Patricio Sepulveda
Principal investigator, leads Amplo Biotechnology, Inc..
BiotechFounder
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2021First federal award
$7.7MFederal grants as PI8 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
8 awards · $7.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| May 12, 2026 | NIH | STTR Phase II Targeted ColQ gene therapy for Congenital Myasthenic Syndromes | $1.4M | Amplo Biotechnology, Inc. |
| Apr 1, 2025 | NIH | STTR Phase II Targeted ColQ gene therapy for Congenital Myasthenic Syndromes | $601K | Amplo Biotechnology, Inc. |
| Sep 13, 2024 | NIH | SBIR Phase II Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes | $3.0M | Amplo Biotechnology, Inc. |
| Jun 18, 2024 | NIH | STTR Phase II Targeted ColQ gene therapy for Congenital Myasthenic Syndromes | $207K | Amplo Biotechnology, Inc. |
| Jun 1, 2023 | NIH | STTR Phase I Targeted ColQ gene therapy for Congenital Myasthenic Syndromes | $493K | Amplo Biotechnology, Inc. with UNIVERSITY OF CALIFORNIA AT DAVIS |
| May 21, 2023 | NIH | SBIR Phase II Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes | $144K | Amplo Biotechnology, Inc. |
| Jun 1, 2022 | NIH | SBIR Phase II Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes | $1.6M | Amplo Biotechnology, Inc. |
| Sep 2, 2021 | NIH | SBIR Phase II Targeted DOK7 gene therapy for Congenital Myasthenic Syndromes | $254K | Amplo Biotechnology, Inc. |
Peer ranks
Federal funding#122
Awards as PI#190
Patents#273
Companies
- Amplo Biotechnology, Inc.Leads (SEC Form D) · Biotech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.